Want to see AXGN full AI Analyst Report?
AXGN Stock Chart & Stats
$39.49
-$0.24(-0.60%)
At close: 4:00 PM EDT
$39.49
-$0.24(-0.60%)
Day’s Range― - ―
52-Week Range$14.79 - $51.06
Previous CloseN/A
Volume750.55K
Average Volume (3M)1.43M
Market Cap
$2.65B
Enterprise Value$2.37K
Total Cash (Recent Filing)$94.57M
Total Debt (Recent Filing)$20.07M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 10, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding53,761,513
10 Day Avg. Volume1,094,003
30 Day Avg. Volume1,433,456
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)11.70
Price to Sales (P/S)6.69
P/FCF Ratio-513.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$55.86Price Target Upside41.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.5
Revenue Forecast (FY)$279.53M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Adoption GrowthStrong growth across breast, extremity, oral and maxillofacial markets indicates expanding surgeon adoption and account productivity. The enlarged commercial organization and growing active-program base support continued demand over the next several quarters.
Strong Gross-margin Business ModelHigh gross margins reflect differentiated peripheral-nerve products and attractive unit economics. Although product mix is pressuring margins, the maintained guidance level suggests the core model can support investment in sales, evidence and product development.
De-risked Balance Sheet And Improving Cash GenerationLow leverage and a sizable equity cushion reduce financing risk while the shift to positive operating and free cash flow improves strategic flexibility. This provides resources to fund commercial expansion and clinical development without relying heavily on debt.
Bears Say
Persistent GAAP Losses And Margin DeteriorationRevenue growth has not yet translated into durable GAAP profitability, and the wider net loss margin weakens earnings quality. Continued losses could constrain internally funded investment and erode the balance-sheet cushion if improvement is delayed.
Operating Expense IntensityCommercial expansion and stock-based compensation are raising the cost base faster than near-term earnings. If productivity gains lag investment, operating leverage may remain limited and higher revenue may produce insufficient bottom-line improvement.
Product-mix And Reimbursement Execution RisksFaster growth in resource-intensive Avance grafts can keep margins below the long-term target until production and pricing actions take effect. Incomplete payer coverage may also slow adoption and make future reimbursement-driven growth less predictable.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $14.79 and its highest was $51.06 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $2.65B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Nov 10, 2026 which is in 76 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Jul 29, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.121 by -$0.001.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.12.
How many shares outstanding does AxoGen have?
AxoGen has 53,761,513 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.12 in its last earnings report, missing expectations of $0.121. Following the earnings report the stock price went up 0.535%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.86 (41.45% Upside)
$55.86 (41.45% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
198.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.39%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
AXGN Company Deck
AXGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: robust revenue growth (Q2 +23.1%), a pronounced acceleration in the Breast market (YTD +47%) that materially expanded Avance volume and adoption, growing active surgeon and account metrics, cash balance strength and raised revenue guidance. Offsetting this optimism are near-term margin pressures driven by an accelerated shift in product mix toward longer, higher-cost Avance grafts, increased operating expenses tied to commercial investment, and pending payer decisions (notably Aetna) that could further accelerate adoption but remain unquantified. Management outlined actionable plans (pricing and production efficiency initiatives) but emphasized these will take time to influence 2026 results. Overall, positives (strong top-line, guidance raise, evidence progress, healthy cash position and commercial momentum) outweigh the manageable operational and margin challenges disclosed.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$55.86
▲(41.45% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.56% Insiders
20.03% Mutual Funds
42.52% Other Institutional Investors
20.84% Public Companies and
Individual Investors











